1. Results of an international crowdsourcing survey on the treatment of non-ST segment elevation ACS patients at high-bleeding risk undergoing percutaneous intervention
- Author
-
Juan Carlos Kaski, Mirvat Alasnag, Jose C. Nicolau, Sean Delaney, Diana A. Gorog, Marco Valgimigli, John J McNeil, Doreen S.H. Tan, Mamas A. Mamas, Juan Tamargo, Philippe Gabriel Steg, Felicita Andreotti, Deepak L. Bhatt, Dominick J. Angiolillo, Alberto J. Lorenzatti, and Albert Ferro
- Subjects
medicine.medical_specialty ,Percutaneous ,medicine.medical_treatment ,030204 cardiovascular system & hematology ,Crowdsourcing ,03 medical and health sciences ,Percutaneous Coronary Intervention ,0302 clinical medicine ,Surveys and Questionnaires ,Intervention (counseling) ,Humans ,Medicine ,ST segment ,030212 general & internal medicine ,Acute Coronary Syndrome ,business.industry ,Percutaneous coronary intervention ,Elevation (emotion) ,Treatment Outcome ,Emergency medicine ,Purinergic P2Y Receptor Antagonists ,Drug Therapy, Combination ,Cardiology and Cardiovascular Medicine ,business ,Platelet Aggregation Inhibitors - Abstract
Choosing an antiplatelet strategy in patients with non-ST segment elevation acute coronary syndrome (NSTE-ACS) at high bleeding risk (HBR), undergoing post-percutaneous coronary intervention (PCI), is complex. We used a unique open-source approach (crowdsourcing) to document if practices varied across a small, global cross-section of antiplatelet prescribers in the post-PCI setting.Five-hundred and fifty-nine professionals from 70 countries (the 'crowd') completed questionnaires containing single- or multi-option and free form questions regarding antiplatelet clinical practice in post-PCI NSTE-ACS patients at HBR. A threshold of 75% defined 'agreement'. There was strong agreement favouring monotherapy with either aspirin or a P2YThe crowdsourcing methodology showed potential as a tool to assess current practice and variation on a global scale and to achieve a broad demographic representation. These preliminary results indicate a high degree of variation with respect to duration of DAPT, monotherapy drug of choice following DAPT and how thrombotic and bleeding risk are assessed. Further investigations should concentrate on interrogating practice variation between key demographic groups.
- Published
- 2021
- Full Text
- View/download PDF